Danish Biotech Genmab Strengthens Shareholder Value Through Stock Repurchases

Rhea-AI Filing Summary

Genmab A/S has filed a Form 6-K reporting transactions related to its ongoing share buy-back program for the period of June 16-20, 2025. The filing includes two key exhibits:

• A company announcement dated June 23, 2025, detailing transactions connected to the share buy-back program
• An appendix providing specific details of the share buyback program's execution for the week of June 16-20, 2025

The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer. This Form 6-K will be incorporated by reference into Genmab's multiple S-8 registration statements (File Numbers: 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876). The company continues to file annual reports under Form 20-F as a foreign private issuer.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JUNE 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated June 23, 2025: Transactions in Connection with Share Buy-back Program
99.1(a)			Appendix - Share buyback program - specification for June 16-20, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: JUNE 23, 2025

FAQ

What share buyback program did GMAB announce in June 2025?

According to the 6-K filing dated June 28, 2025, Genmab A/S (GMAB) reported transactions related to their share buy-back program, with specific details for the period of June 16-20, 2025 included in an appendix to the filing.

Who signed GMAB's June 2025 6-K filing?

The 6-K filing was signed by Anthony Pagano, who serves as Executive Vice President & Chief Financial Officer of Genmab A/S.

What SEC registration statements does GMAB's June 2025 6-K get incorporated into?

The 6-K filing is incorporated by reference into Genmab's Form S-8 registration statements with file numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.

Where is GMAB's principal executive office located?

Genmab A/S's principal executive office is located at Carl Jacobsens Vej 30, 2500 Valby, Denmark, with phone number +45 70 20 27 28.